The effect of Quadruple Therapy with Saccharomyces Boulardii or a Lactobacillus Reuteri Strain DSMZ 17648 Supplement (PYLOSHOT®) on Eradication of Helicobacter Pylori and Treatment Side Effects
Phase 3
Recruiting
- Conditions
- Gastric infection with Helicobacter pylori.
- Registration Number
- IRCT20200106046021N1
- Lead Sponsor
- Birjand University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 156
Inclusion Criteria
Symptoms of H. pylori-positive as Confirmed by Clinical, Endoscopic, and Pathological Reports.
Exclusion Criteria
Pregnancy and lactation
Patients with Liver, CardioPulmonary, Renal, Neoplastic Diseases
People taking Proton Pump Inhibitors, Bismuth Salts, or Probiotics for the past 4 weeks and any Immuno Suppressive Drugs
Surgery such as Gastrectomy or Gastric Bypass
The existence of Autoimmune Diseases
IBD (Inflammatory Bowel Disease)
Organ Transplant
Weight loss over 3kg over the past three months
Previous History of Helicobacter Pylori Eradication
Oral Antibiotic use in less than 3 months
Alcohol abuse
Participate in Other Clinical Trials Concurrently
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean recovery time in study groups. Timepoint: 2 and 6 weeks after the end of treatment. Method of measurement: Stool Antigen Test.;Frequency distribution of treatment side effects in study groups. Timepoint: During treatment weekly. Method of measurement: Using the questionnaire.
- Secondary Outcome Measures
Name Time Method